Welcome to a new edition of our Updates on Myeloproliferative Neoplasms (MPNs) newsletter. This month, we provide links to articles on the relationship between symptom burden and medical disability leave among patients with MPNs, an update on the in-process U.S. Food and Drug Administration approval for fedratinib for the treatment of myelofibrosis, and new data on the long-term outcomes of patients with myelofibrosis who undergo stem cell transplant. We also spotlight a review of recent trials of ruxolitinib in patients with polycythemia vera and myelofibrosis, as well as preclinical data on the CDK6 protein’s role in JAK2V617F-initiated MPNs.
Also, as promised, I’m taking your questions about real-life challenges encountered in your day-to-day practice and providing informative video answers. This month, I’ll be answering the following question: What are some best practices for handling iron deficiency in a patient with polycythemia vera?
Want your question featured in the next newsletter? Email it to email@example.com.
I’d also like to spotlight two helpful resources from our new MPN Resources Center:
- The Building Blocks of Hope is a free, downloadable PDF that helps educate patients with MPNs and caregivers about the basics of disease state pathophysiology, diagnostic processes, symptoms of the disease, and treatment options. It also provides patient-focused resources for social support.
- MPN Cancer Connection supplies a comprehensive list of links to financial resources for patients with MPNs on areas including out-of-pocket costs, co-pay and medication assistance, airfare, and federal benefits.
Please feel free to share this newsletter and our enduring resources with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at firstname.lastname@example.org at any time.
Lindsey Lyle, MS, PA-C
Senior Instructor, Blood Cancers and Bone Marrow Transplant Program
University of Colorado, Anschutz Medical Campus